Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
2(50%)
Results Posted
0%(0 trials)

Phase Distribution

Ph not_applicable
1
25%

Phase Distribution

0

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution1 total trials
N/ANon-phased studies
1(100.0%)

Highest Phase Reached

Unknown

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

4

all time

Status Distribution
Active(2)
Completed(2)

Detailed Status

Recruiting2
Completed2

Development Timeline

Analytics

Development Status

Total Trials
4
Active
2
Success Rate
100.0%
Most Advanced
N/A

Trials by Phase

N/A1 (100.0%)

Trials by Status

recruiting250%
completed250%

Recent Activity

2 active trials
Showing 4 of 4
recruiting

Metabolic Reprogramming and Microenvironment in Pancreatic Adenocarcinoma

NCT07664891
completednot_applicable

Identifying Immune-related Biomarkers to Predict the Efficacy of Cancer Immunotherapy

NCT03595813
recruiting

Registering Genomics and Imaging of Tumors (ReGIT)

NCT05386043
completed

The Role of the Pregnane X Receptor (PXR) in Indole Signaling and Intestinal Permeability in Inflammatory Bowel Disease

NCT04089501

Clinical Trials (4)

Showing 4 of 4 trials
NCT07664891

Metabolic Reprogramming and Microenvironment in Pancreatic Adenocarcinoma

Recruiting
NCT03595813Not Applicable

Identifying Immune-related Biomarkers to Predict the Efficacy of Cancer Immunotherapy

Completed
NCT05386043

Registering Genomics and Imaging of Tumors (ReGIT)

Recruiting
NCT04089501

The Role of the Pregnane X Receptor (PXR) in Indole Signaling and Intestinal Permeability in Inflammatory Bowel Disease

Completed

All 4 trials loaded

Drug Details

Intervention Type
OTHER
Total Trials
4